Coccidioidomycosis (Valley Fever) is difficult to diagnose due to lack of awareness and symptoms imitating many other respiratory infections. There were over 15,000 cases reported to the CDC in 2018. Valley Fever is said to cause nearly 30% of all community acquired pneumonia (CAP) cases in highly endemic areas.1
This assay offers two 96-microwell plates and two different antigen preparations, which greatly reduces the potential for error and enhances the sensitivity and specificity compared to competitive assays.
Serum | Sensitivity | Specificity | PPV | NPV |
---|---|---|---|---|
CF/ID | 98% | 99% | 96% | 95.5% |
Coccidioides Antibody EIA | 96 tests | CAB102 |
---|